MarketsMOJO Downgrades SMS Pharmaceuticals Ltd to Sell Amid Valuation and Quality Concerns

Quality Assessment Deteriorates to Below Average

The primary driver behind the rating downgrade is a decline in the company’s quality grade, which has shifted from average to below average. Over the past five years, SMS Pharmaceuticals has recorded a modest sales growth rate of 9.51% and an EBIT growth of 5.95%, both of which lag behind many of its pharmaceutical peers. The company’s average EBIT to interest coverage ratio stands at 4.06, indicating moderate ability to service debt, but its debt to EBITDA ratio of 2.95 and net debt to equity ratio of 0.46 suggest a cautious stance on leverage.

Return metrics further highlight concerns: the average return on capital employed (ROCE) is 10.39%, while return on equity (ROE) averages 9.24%. These figures are below the industry’s stronger performers such as Ajanta Pharma and Gland Pharma, which maintain good quality grades. Additionally, SMS Pharma’s dividend payout ratio is a low 4.08%, and institutional holding is minimal at 3.33%, signalling limited external confidence. The company also has a relatively high pledged shares percentage of 17.99%, which may raise governance questions.

Valuation Moves to Very Expensive Territory

SMS Pharmaceuticals’ valuation grade has worsened from expensive to very expensive, reflecting stretched market multiples. The stock currently trades at a price-to-earnings (PE) ratio of 34.90, which is high relative to its earnings growth and peers. Its price-to-book value stands at 4.53, while enterprise value to EBIT and EBITDA ratios are 29.52 and 22.64 respectively, underscoring a premium valuation.

The company’s PEG ratio is 1.05, indicating that the price is somewhat aligned with earnings growth, but the dividend yield is negligible at 0.10%, offering little income return to investors. Despite a latest ROCE of 11.89% and ROE of 12.98%, these returns do not justify the current valuation premium, especially when compared to peers like Ajanta Pharma and Gland Pharma, which offer better growth prospects at similar or lower valuations.

Financial Trend Shows Mixed Signals Despite Positive Quarterly Results

While SMS Pharmaceuticals has reported positive financial performance in the latest quarter (Q4 FY25-26), including a highest quarterly PAT of ₹32.71 crores and EPS of ₹3.49, its long-term financial trend remains subdued. The company’s net sales have grown at a compounded annual rate of 9.51% over five years, and operating profit has increased by only 5.95% annually, indicating slow growth momentum.

Debtors turnover ratio for the half-year is strong at 4.11 times, reflecting efficient receivables management. However, the company’s average ROCE of 9.88% is weak relative to industry standards, limiting its ability to generate value from capital employed. Despite generating a 41.45% return over the past year, SMS Pharma’s financial fundamentals do not fully support this performance, suggesting that the stock price may be driven more by market sentiment than by underlying earnings strength.

Technical Indicators Shift to Mildly Bullish but Show Caution

The technical grade for SMS Pharmaceuticals has been downgraded from bullish to mildly bullish, reflecting a more cautious market outlook. Weekly MACD and KST indicators are mildly bearish, while monthly signals remain bullish, indicating mixed momentum. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, suggesting a lack of strong directional conviction.

Bollinger Bands and daily moving averages are mildly bullish, but the On-Balance Volume (OBV) shows no clear trend weekly, though it is bullish monthly. Dow Theory assessments also present a split picture, mildly bearish weekly but bullish monthly. This technical ambiguity, combined with a recent one-week price decline of 6.89% against a Sensex gain of 1.56%, signals potential near-term volatility.

Stock Performance Outpaces Sensex but Faces Fundamental Challenges

Over multiple time horizons, SMS Pharmaceuticals has delivered impressive stock returns relative to the Sensex benchmark. The stock has generated a 41.45% return over the past year compared to the Sensex’s -6.40%, and a remarkable 335.13% return over three years versus the Sensex’s 23.62%. Even over a decade, SMS Pharma’s 315.78% return significantly outperforms the Sensex’s 195.54%.

However, these gains have not been matched by commensurate improvements in fundamental quality or valuation metrics. The company’s current market price of ₹370.25 is down 2.87% on the day, trading below its 52-week high of ₹446.50 but well above the 52-week low of ₹208.20. This price action, combined with the downgrade to a Sell rating and a Mojo Score of 43.0, suggests investors should exercise caution.

Peer Comparison Highlights Relative Weakness

When compared with peers in the Pharmaceuticals & Biotechnology sector, SMS Pharmaceuticals’ quality and valuation metrics lag behind industry leaders. Companies such as Ajanta Pharma, Gland Pharma, and Piramal Pharma maintain good to average quality grades and more balanced valuations. For instance, Ajanta Pharma’s PE ratio is slightly higher at 36.34 but is supported by stronger growth and quality metrics.

SMS Pharma’s below average quality grade contrasts with the good grades of most peers, and its very expensive valuation grade places it at a disadvantage. This disparity underscores the rationale behind the downgrade and highlights the need for investors to consider alternative opportunities within the sector.

Conclusion: Downgrade Reflects Fundamental and Valuation Risks

The downgrade of SMS Pharmaceuticals Ltd from Hold to Sell is driven by a combination of deteriorating quality metrics, stretched valuation multiples, mixed financial trends, and cautious technical signals. Despite strong stock price appreciation and positive quarterly earnings, the company’s long-term growth and capital efficiency remain weak relative to peers.

Investors should weigh the risks associated with the company’s below average quality grade, very expensive valuation, and uncertain technical outlook before considering exposure. The downgrade serves as a reminder that strong past returns do not guarantee future performance, especially when underlying fundamentals are under pressure.

Key Financial Metrics at a Glance:

• 5-year Sales Growth: 9.51%
• 5-year EBIT Growth: 5.95%
• Average ROCE: 10.39%
• Average ROE: 9.24%
• PE Ratio: 34.90
• Price to Book Value: 4.53
• Debt to EBITDA: 2.95
• Dividend Yield: 0.10%
• PEG Ratio: 1.05

Market Capitalisation and Trading Range:

SMS Pharmaceuticals is classified as a small-cap stock, currently trading at ₹370.25, down from the previous close of ₹381.20. The stock’s 52-week trading range spans from ₹208.20 to ₹446.50, reflecting significant volatility over the past year.

Shareholding and Governance:

The majority shareholding remains with promoters, while institutional holding is low at 3.33%. The relatively high pledged shares percentage of 17.99% may be a concern for governance-conscious investors.

Overall, the downgrade to Sell by MarketsMOJO reflects a cautious stance on SMS Pharmaceuticals Ltd, urging investors to consider the company’s fundamental and valuation challenges in the context of their portfolios.

53% Discount is LIVE - Get MojoOne + Stock of the Week for 3 Years Start Today